Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 1.00 |
| ▸ | GLB1 | P16278 | 1/20 | 0.77 |
| ▸ | GBA1 | P04062 | 10/20 | 0.74 |
| ▸ | GBA2 | Q9HCG7 | 12/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | UGCG | Q16739 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272922 | 1.00 | GUSB (1.00) | GUSBGLB1GBA1GBA2GAA | |
| SCHEMBL1857461 | 1.00 | GUSB (1.00) | GUSBGLB1GBA1GBA2GAA | |
| SCHEMBL3378221 | 0.96 | GUSB (0.92) | GUSBGLB1GBA1GBA2GAA | |
| SCHEMBL15599059 | 0.96 | GUSB (0.92) | GUSBGLB1GBA1GBA2GAA | |
| SCHEMBL2430985 | 0.96 | GUSB (0.92) | GUSBGLB1GBA1GBA2GAA | |
| SCHEMBL2430986 | 0.96 | GUSB (0.92) | GUSBGLB1GBA1GBA2GAA | |
| SCHEMBL15599026 | 0.96 | GUSB (0.92) | GUSBGLB1GBA1GBA2GAA | |
| SCHEMBL15599058 | 0.96 | GUSB (0.92) | GUSBGLB1GBA1GBA2GAA | |
| SCHEMBL2435897 | 0.96 | GUSB (0.92) | GUSBGLB1GBA1GBA2GAA | |
| SCHEMBL2430983 | 0.96 | GUSB (0.92) | GUSBGLB1GBA1GBA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | GUSB 1090/4885GLB1 211/4885GBA1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.